Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan in Acute Decompensated Heart Failure
NCT07262723Phase 3Not yet recruiting
- Sponsor
- Chattogram Medical College
- Start
- Dec 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of levosimendan in heart failure (HF) (2 arms), sponsored by Chattogram Medical College. Primary endpoint: Clinical Improvement in Heart Failure Symptoms at 5 days. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
levosimendan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT07262723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07262723.